111 related articles for article (PubMed ID: 15018602)
1. Use of medical services by methylphenidate-treated children in the general population.
Miller AR; Brehaut JC; Raina P; McGrail KM; Armstrong RW
Ambul Pediatr; 2004; 4(2):174-80. PubMed ID: 15018602
[TBL] [Abstract][Full Text] [Related]
2. Injury prevention by medication among children with attention-deficit/hyperactivity disorder: a case-only study.
Mikolajczyk R; Horn J; Schmedt N; Langner I; Lindemann C; Garbe E
JAMA Pediatr; 2015 Apr; 169(4):391-5. PubMed ID: 25686215
[TBL] [Abstract][Full Text] [Related]
3. Treatment outcomes with methylphenidate formulations among patients with ADHD: retrospective claims analysis of a managed care population.
Hodgkins P; Sasané R; Christensen L; Harley C; Liu F
Curr Med Res Opin; 2011; 27 Suppl 2():53-62. PubMed ID: 21973231
[TBL] [Abstract][Full Text] [Related]
4. Dosage of methylphenidate and traumatic brain injury in ADHD: a population-based study in Taiwan.
Liao YT; Yang YH; Kuo TY; Liang HY; Huang KY; Wang TN; Lee Y; McIntyre RS; Chen VC
Eur Child Adolesc Psychiatry; 2018 Mar; 27(3):279-288. PubMed ID: 28856464
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of reboxetine in the treatment of attention-deficit/hyperactivity disorder in boys with intolerance to methylphenidate: an open-label, 8-week, methylphenidate-controlled trial.
Cohen-Yavin I; Yoran-Hegesh R; Strous RD; Kotler M; Weizman A; Spivak B
Clin Neuropharmacol; 2009; 32(4):179-82. PubMed ID: 19644227
[TBL] [Abstract][Full Text] [Related]
6. Comorbidities in ADHD children treated with methylphenidate: a database study.
Kraut AA; Langner I; Lindemann C; Banaschewski T; Petermann U; Petermann F; Mikolajczyk RT; Garbe E
BMC Psychiatry; 2013 Jan; 13():11. PubMed ID: 23294623
[TBL] [Abstract][Full Text] [Related]
7. Effect of methylphenidate formulation for attention deficit hyperactivity disorder on patterns and outcomes of treatment.
Lage M; Hwang P
J Child Adolesc Psychopharmacol; 2004; 14(4):575-81. PubMed ID: 15662149
[TBL] [Abstract][Full Text] [Related]
8. Initiation and Persistence of Pharmacotherapy for Youths with Attention Deficit Hyperactivity Disorder in Taiwan.
Wang LJ; Yang KC; Lee SY; Yang CJ; Huang TS; Lee TL; Yuan SS; Shyu YC
PLoS One; 2016; 11(8):e0161061. PubMed ID: 27518196
[TBL] [Abstract][Full Text] [Related]
9. Effects of methylphenidate on body index and physical fitness in Korean children with attention deficit hyperactivity disorder.
Kang KD; Yun SW; Chung U; Kim TH; Park JH; Park IH; Han DH
Hum Psychopharmacol; 2016 Mar; 31(2):76-82. PubMed ID: 26756111
[TBL] [Abstract][Full Text] [Related]
10. No elevated genomic damage in children and adolescents with attention deficit/hyperactivity disorder after methylphenidate therapy.
Walitza S; Kämpf K; Artamonov N; Romanos M; Gnana Oli R; Wirth S; Warnke A; Gerlach M; Stopper H
Toxicol Lett; 2009 Jan; 184(1):38-43. PubMed ID: 19015014
[TBL] [Abstract][Full Text] [Related]
11. Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD.
Niederkirchner K; Slawik L; Wermelskirchen D; Rettig K; Schäuble B
Expert Rev Neurother; 2011 Apr; 11(4):499-508. PubMed ID: 21469923
[TBL] [Abstract][Full Text] [Related]
12. Effects of Atomoxetine and Osmotic Release Oral System-Methylphenidate on Executive Functions in Patients with Combined Type Attention-Deficit/Hyperactivity Disorder.
Ince Tasdelen B; Karakaya E; Oztop DB
J Child Adolesc Psychopharmacol; 2015 Aug; 25(6):494-500. PubMed ID: 26218871
[TBL] [Abstract][Full Text] [Related]
13. [Methylphenidate prescriptions in the city of Cologne: overrepresentation of privately insured patients. Results of an analysis based on prescription data].
Bessou H; Zeeb H; Puteanus U
Gesundheitswesen; 2007 May; 69(5):292-6. PubMed ID: 17582546
[TBL] [Abstract][Full Text] [Related]
14. Childhood behavior disorders and injuries among children and youth: a population-based study.
Brehaut JC; Miller A; Raina P; McGrail KM
Pediatrics; 2003 Feb; 111(2):262-9. PubMed ID: 12563049
[TBL] [Abstract][Full Text] [Related]
15. Dopamine transporter genotype influences the physiological response to medication in ADHD.
Gilbert DL; Wang Z; Sallee FR; Ridel KR; Merhar S; Zhang J; Lipps TD; White C; Badreldin N; Wassermann EM
Brain; 2006 Aug; 129(Pt 8):2038-46. PubMed ID: 16760197
[TBL] [Abstract][Full Text] [Related]
16. Children's persistence with methylphenidate therapy: a population-based study.
Miller AR; Lalonde CE; McGrail KM
Can J Psychiatry; 2004 Nov; 49(11):761-8. PubMed ID: 15633854
[TBL] [Abstract][Full Text] [Related]
17. Continuity of methylphenidate treatment for attention-deficit/hyperactivity disorder.
Marcus SC; Wan GJ; Kemner JE; Olfson M
Arch Pediatr Adolesc Med; 2005 Jun; 159(6):572-8. PubMed ID: 15939858
[TBL] [Abstract][Full Text] [Related]
18. Prescription of methylphenidate to children and youth, 1990-1996.
Miller AR; Lalonde CE; McGrail KM; Armstrong RW
CMAJ; 2001 Nov; 165(11):1489-94. PubMed ID: 11762572
[TBL] [Abstract][Full Text] [Related]
19. [EPIDEMIOLOGY OF RITALIN PRESCRIPTION IN 6-18 YEARS OLD ISRAELI CHILDREN - TIME TO CHANGE POLICY].
Jaber L; Rigler S; Shuper A; Diamond G
Harefuah; 2017 Jul; 156(7):460-464. PubMed ID: 28786270
[TBL] [Abstract][Full Text] [Related]
20. Differential effects of methylphenidate and atomoxetine on attentional processes in children with ADHD: an event-related potential study using the Attention Network Test.
Kratz O; Studer P; Baack J; Malcherek S; Erbe K; Moll GH; Heinrich H
Prog Neuropsychopharmacol Biol Psychiatry; 2012 Apr; 37(1):81-9. PubMed ID: 22227291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
